论文部分内容阅读
目的:探讨针对重症急性胰腺炎患者,观察选择奥曲肽完成治疗后的临床效果表现。方法:选取我院2010年10月-2014年10月重症急性胰腺炎患者90例。通过随机数表法完成重症急性胰腺炎患者的随机分组。C2组(对照组45例):临床选择常规治疗的方法;C1组(观察组45例):临床选择常规治疗+奥曲肽治疗的方法;对比两组重症急性胰腺炎患者在腹痛症状改善时间以及血尿淀粉酶恢复时间等方面存在的差异。结果:两组重症急性胰腺炎患者分别完成治疗后,在腹痛症状改善时间以及血尿淀粉酶恢复时间两方面,C1组少于C2组患者明显(P<0.05)。在胰腺水肿症状缓解率方面,C1组高于C2组患者明显(P<0.05)。结论:针对重症急性胰腺炎患者,临床选择奥曲肽进行治疗,针对胰腺酶的抑制作用以及消化作用可以进行有效抑制,从而显著改善患者的临床症状以及体征表现,最终将患者血尿淀粉酶水平有效恢复,有效避免临床出现严重并发症的现象,凸显临床应用价值。
Objective: To investigate the clinical effect of selective octreotide in the treatment of patients with severe acute pancreatitis. Methods: 90 cases of severe acute pancreatitis in our hospital from October 2010 to October 2014 were selected. Randomized patients in severe acute pancreatitis were randomized by random number table. C2 group (control group, 45 cases): clinical choose routine treatment method; C1 group (observation group 45 cases): clinical choose conventional treatment + octreotide treatment method; compared two groups of patients with severe acute pancreatitis in the improvement of abdominal pain symptoms and hematuria Amylase recovery time and so there are differences. Results: After treatment of two groups of patients with severe acute pancreatitis, the patients in C1 group were less than C2 group (P <0.05) in terms of improvement of abdominal pain symptom and recovery time of hematuria and amylase. In the rate of response to pancreatic edema, C1 group was significantly higher than C2 group (P <0.05). Conclusion: For patients with severe acute pancreatitis, the clinical choice of octreotide for the treatment of pancreatic enzyme inhibition and digestion can be effectively inhibited, thereby significantly improving the patient’s clinical symptoms and signs of performance, and ultimately the patient’s urine amylase levels effectively restored, Effectively avoid serious clinical complications, highlighting the clinical value.